F2G
F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases
Total raised
€211M
€210,609,568
Funding rounds
5
Investors
18
distinct backers
Active since
2008-07
latest 2022-08
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood24
base rate 30% for Other
- ▼ Overdue vs cohort gap
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood28
base rate 12% (2+ rounds)
- ▲ 5 rounds raised
- ▲ €100M+ raised
- ▲ 28y since founding
Timing: overdue vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
5 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-08-04 | Other | €69M | Advent Life Sciences,Cowen Healthcare Investments,Forbion Capital Partners,Morningside Ventures,Novo Holdings,Sofinnova Partners | View deal → |
| 2020-08-12 | Other | €52M | Cowen Healthcare Investments | View deal → |
| 2016-06-01 | Growth/Late | €55M | Advent Venture Partners,Aisling Capital,Brace Pharma,Merifin Capital,Novartis Venture Fund,Novo A+3 more | View deal → |
| 2012-09-01 | Growth/Late | €27M | Advent Venture Partners,Astellas Venture,K Nominees,Merifin Capital,Novartis Venture Fund,Sunstone Capital | View deal → |
| 2008-08-01 | Early VC | €8.8M | Astellas Venture,BankInvest,K Nominees,Merifin Capital | View deal → |
Investors
18Related news
- F2G Raises $70M in Financingfinsmes.com · 2022-08
- finsmes.com
- finsmes.com